⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Fisetin
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-05-21 — A photo-responsive, fisetin-functionalized DNA nanocage for programmed therapy to accelerate early-stage wound healing in aged skin.: [animal-model] Aged-mouse wound-healing study reports that a photo-responsive tetrahedral DNA nanocage co-delivering fisetin and a miR-29-targeting antisense oligonucleotide cleared senescent cells and accelerated early-stage wound repair through temporally programmed release; these combination-platform results do not establish efficacy of oral fisetin alone or human wound-healing benefit. [animal-model] (novelty: 3)
- 2026-09-30 — An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer: Open-label pilot includes a fisetin-alone arm in adult childhood-cancer survivors targeting p16INK4a senescent-cell burden and frailty measures — adds a cancer-survivor subpopulation to the fisetin senolytic clinical program; no efficacy data yet. [expert-opinion] (novelty: 3)
- 2026-10-06 — Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan: Phenotypic drug-discovery screen generated fisetin-derived analogs SR29384 and SR31133 with broader senescent-cell-type coverage and improved healthspan markers in aging mice — suggests the parent flavonoid scaffold is tractable to optimization, preclinical only. [animal-model] (novelty: 3)
- 2026-10-01 — Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan.: Preclinical structure-activity progress on the fisetin scaffold: phenotypic drug discovery yielded SR29384 and SR31133, fisetin-derived flavonoid senolytics with enhanced potency across senescent cell types and improved healthspan markers in aging mice — suggests the parent molecule is not the optimized form of its own senolytic activity. [animal-model] [animal-model] (novelty: 3)
- 2026-09-27 — Discovery of Fisetin as a potent and cell-active ACVR2A inhibitor.: In-vitro enzymology plus C2C12 myotube assay identified fisetin as a potent cell-active ACVR2A inhibitor that suppresses TGF-β/Smad signaling and blocks Activin A-induced myotube atrophy — a novel muscle-preserving mechanism distinct from fisetin’s senolytic framing, but no in-vivo efficacy and PK remains poor. [mechanism-plausible] (novelty: 3)
- 2026-09-25 — Fisetin to Improve Vascular Function in Older Adults: Pilot clinical trial registered testing intermittent fisetin for vascular endothelial function and aortic stiffness in older adults, with mechanistic endpoints on mitochondrial oxidative stress, cellular senescence, and circulating SASP — design-stage clinical probe, no efficacy readout. [expert-opinion] (novelty: 3)
- 2026-07-30 — Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors: Phase II trial launched testing fisetin combined with exercise to prevent frailty in breast cancer survivors via senescent-cell clearance — extends the fisetin senolytic clinical program into a cancer-survivor aging subpopulation with a combined exercise arm; no efficacy readout yet. [expert-opinion] (novelty: 3)
- 2026-08-10 — Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers: 12-week RCT protocol registered testing daily fisetin 500 mg alone or combined with urolithin A (200+300 mg) vs placebo in middle-aged/older adults for sleep quality and aging biomarkers (methylation, inflammation, microbiome) — first sleep-endpoint clinical probe for fisetin, no readout yet. [expert-opinion] (novelty: 3)
- 2026-07-01 — Ongoing Lung Decline With Age Intensified Response: Phase II pilot RCT of short-course high-dose fisetin registered in adults 60+ (with and without smoking history) with lung function and cellular-senescence biomarker endpoints — a design-stage clinical probe of the senolytic rationale, not a results readout. [expert-opinion] (novelty: 3)
- 2026-08-03 — Natural Bioactive Compounds Targeting Key Hallmarks of Aging: Functional Food Potential of Spermidine, Fisetin, Berberine, and Urolithin A.: Narrative review frames fisetin as the senolytic component of a proposed spermidine/fisetin/berberine/urolithin A functional-food combination targeting complementary aging hallmarks; no new trial data. [mechanism-plausible] (novelty: 3)
Open questions
Related
Contributing findings
Senescence-Associated Secretory Phenotype (SASP) and Atherosclerotic Plaque Inflammation: Natural Product-Based Interventions and Implications for Personalized Therapy.
10-nov-2026
novelty 2
per-area 2
strengthens
Is there a role for senotherapeutics in the treatment of giant cell arteritis?
07-oct-2026
novelty 2
per-area 2
mentions
Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan
06-oct-2026
novelty 3
per-area 3
strengthens
Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan.
01-oct-2026
novelty 3
per-area 3
strengthens
An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer
30-sep-2026
novelty 3
per-area 3
strengthens
Discovery of Fisetin as a potent and cell-active ACVR2A inhibitor.
27-sep-2026
novelty 3
per-area 3
strengthens
Fisetin to Improve Vascular Function in Older Adults
25-sep-2026
novelty 3
per-area 3
strengthens
Retraction notice to "Fisetin as a caloric restriction mimetic protects rat brain against aging induced oxidative stress, apoptosis and neurodegeneration" [Life Sci. 193 (2018) 171-179].
23-sep-2026
novelty 2
per-area 2
weakens
Clinical Translation of Fisetin for Age-Related Diseases: Current Evidence and Future Opportunities.
14-sep-2026
novelty 2
per-area 2
strengthens
Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers
10-aug-2026
novelty 3
per-area 3
strengthens
Natural Bioactive Compounds Targeting Key Hallmarks of Aging: Functional Food Potential of Spermidine, Fisetin, Berberine, and Urolithin A.
03-aug-2026
novelty 3
per-area 3
strengthens
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
30-jul-2026
novelty 3
per-area 3
strengthens
Ongoing Lung Decline With Age Intensified Response
01-jul-2026
novelty 3
per-area 3
strengthens
A photo-responsive, fisetin-functionalized DNA nanocage for programmed therapy to accelerate early-stage wound healing in aged skin.
21-may-2026
novelty 3
per-area 3
strengthens